Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

D. van der Heijde, M.H. Schiff, J. Sieper, A.J. Kivitz, R.L. Wong, H. Kupper, B.A.C. Dijkmans, P.J. Mease, J.C. Davis

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)922-929
JournalAnnals of the Rheumatic Diseases
Volume68
Issue number6
DOIs
Publication statusPublished - 2009

Cite this